An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with Pridopidine — Suma Babu (MASSACHUSETTS GENERA
The Sigma 1 Receptor (S1R) has emerged as an attractive therapeutic target in ALS. Mutations in the S1R are causative of ALS and the degree of loss of function in S1R protein determines age of onset.
| Project title | An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with Pridopidine |
|---|---|
| Project number | 5U01NS136021-02 |
| PI name | Suma Babu |
| Institution | MASSACHUSETTS GENERAL HOSPITAL |
| Funding mechanism | U01 |
| Agency | NINDS |
| Award amount | $9.83M |
| Fiscal year | 2024 |
| Project start | 2023-09-25T00:00:00 |
| Project end | 2027-08-31T00:00:00 |
| Abstract | The Sigma 1 Receptor (S1R) has emerged as an attractive therapeutic target in ALS. Mutations in the S1R are causative of ALS and the degree of loss of function in S1R protein determines age of onset. |
| Key terms | <2-Amino-6-trifluoromethoxybenzothiazole><ALS patients><Affect><Age of Onset><Agonist><Amyotrophic L |
$799/mo
Try GrantRadar →